Microvast Holdings announces departure of chief financial officer
FORT MYERS, Fla. - NeoGenomics, Inc. (NASDAQ:NEO), a provider of cancer diagnostics with annual revenue of $672 million and 10.1% year-over-year growth, announced the launch of its PanTracer Family of genomic profiling tests and the Paletrra spatial proteomics platform at the American Society of Clinical Oncology (ASCO) Annual Meeting scheduled for May 30 to June 3, 2025. The new offerings are aimed at enhancing precision medicine in oncology by delivering detailed insights into advanced solid tumors and the tumor microenvironment. According to InvestingPro analysis, while currently unprofitable, the company is expected to achieve profitability this year, making this product launch particularly significant for its growth trajectory.
The PanTracer Family includes the PanTracer Tissue for profiling from tissue samples, PanTracer LBx for liquid biopsy applications, and PanTracer Tissue + HRD, which includes homologous recombination deficiency testing. These tests are designed to support oncologists in making informed treatment decisions, particularly when tissue samples are unavailable or insufficient.
Paletrra, an AI-driven platform, offers advanced spatial proteomics analysis, providing researchers with high-plex, image-based insights into tissue samples. This tool is expected to assist both large and emerging biopharma companies in accelerating therapeutic decision-making.
Warren Stone, President & Chief Operating Officer at NeoGenomics, stated, "The debut of the PanTracer Family and Paletrra represents a significant milestone for NeoGenomics and a step forward in precision oncology." He emphasized the company’s commitment to transforming cancer care through innovative diagnostic solutions.
NeoGenomics will present a scientific poster and two abstracts at the ASCO meeting, highlighting the company’s contributions to oncology research and diagnostics. The abstracts cover a real-world analysis of folate receptor alpha expression in over 6000 patients, the cancer fusionome in K-RAS wild-type pancreatic cancer, and the analytical validation of the NEO | PanTracer LBx assay.
The company, headquartered in Fort Myers, FL, operates a network of laboratories in the US and a laboratory in the United Kingdom, providing a range of cancer genetics testing and information services. With a market capitalization of $965 million and a current ratio of 2.05, InvestingPro data shows the company maintains strong liquidity to support its operations. Despite recent stock volatility and a 57.7% decline over the past six months, InvestingPro’s Fair Value analysis suggests the stock may be undervalued at current levels. For deeper insights into NeoGenomics’ financial health and growth prospects, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro, which covers this and 1,400+ other top US stocks.
This news is based on a press release statement and includes forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. These statements have not been independently verified and reflect the company’s expectations as of today.
In other recent news, NeoGenomics reported its Q1 2025 earnings, revealing a revenue of $168 million, which missed the forecasted $171.35 million. However, the company’s earnings per share (EPS) stood at $0, surpassing the forecasted -$0.01. NeoGenomics has fully repaid its $201.25 million convertible debt, demonstrating strong financial management and liquidity. Additionally, the company launched a new diagnostic assay, c-MET CDx for NSCLC, designed to aid in the selection of targeted therapies for advanced non-small cell lung cancer. NeoGenomics has maintained its full-year revenue guidance, projecting 13-15% growth. The company’s recent acquisition of Pathline is expected to contribute to future revenue, although it may initially impact earnings negatively. NeoGenomics continues to expand its test offerings, with a focus on next-generation sequencing (NGS) products. The company has also entered a collaboration with Ultima Genomics to enhance its oncology test offerings.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.